カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

ゴナドトロピン放出ホルモン拮抗薬の世界市場2022：ペプチド、低分子

◆英語タイトル：Global Gonadotropin-releasing Hormone Antagonists Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
	◆商品コード：GIR22NO19362 ◆発行会社（リサーチ会社）：GlobalInfoResearch ◆発行日：2022年11月（※2025年版があります。お問い合わせください。） ◆ページ数：92 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（注文後2-3日） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,480 ⇒換算￥528,960	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,220 ⇒換算￥793,440	見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）	USD6,960 ⇒換算￥1,057,920	見積依頼/購入/質問フォーム

★GlobalInfoResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

ゴナドトロピン放出ホルモン拮抗薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のゴナドトロピン放出ホルモン拮抗薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

ゴナドトロピン放出ホルモン拮抗薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・ペプチド、低分子

用途別セグメントは次のように区分されます。
・前立腺がん、子宮内膜症、子宮筋腫、女性不妊症、その他

世界のゴナドトロピン放出ホルモン拮抗薬市場の主要な市場プレーヤーは以下のとおりです。
・AbbVie、Takeda、Astellas、Kissei、Veru Inc、Myovant Sciences、AstraZeneca、Ferring Pharmaceuticals、Jiangsu Hengrui Medicine Co

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、ゴナドトロピン放出ホルモン拮抗薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なゴナドトロピン放出ホルモン拮抗薬メーカーの企業概要、2019年～2022年までのゴナドトロピン放出ホルモン拮抗薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なゴナドトロピン放出ホルモン拮抗薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別ゴナドトロピン放出ホルモン拮抗薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのゴナドトロピン放出ホルモン拮抗薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのゴナドトロピン放出ホルモン拮抗薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびゴナドトロピン放出ホルモン拮抗薬の産業チェーンを掲載しています。
・第13、14、15章では、ゴナドトロピン放出ホルモン拮抗薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- ゴナドトロピン放出ホルモン拮抗薬の概要
- 種類別分析（2017年vs2021年vs2028年）：ペプチド、低分子
- 用途別分析（2017年vs2021年vs2028年）：前立腺がん、子宮内膜症、子宮筋腫、女性不妊症、その他
- 世界のゴナドトロピン放出ホルモン拮抗薬市場規模・予測
- 世界のゴナドトロピン放出ホルモン拮抗薬生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- AbbVie、Takeda、Astellas、Kissei、Veru Inc、Myovant Sciences、AstraZeneca、Ferring Pharmaceuticals、Jiangsu Hengrui Medicine Co
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：ペプチド、低分子
・用途別分析2017年-2028年：前立腺がん、子宮内膜症、子宮筋腫、女性不妊症、その他
・ゴナドトロピン放出ホルモン拮抗薬の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・ゴナドトロピン放出ホルモン拮抗薬のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・ゴナドトロピン放出ホルモン拮抗薬のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・ゴナドトロピン放出ホルモン拮抗薬の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・ゴナドトロピン放出ホルモン拮抗薬の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Gonadotropin-releasing Hormone Antagonists market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Gonadotropin-releasing Hormone Antagonists market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Prostate Cancer accounting for % of the Gonadotropin-releasing Hormone Antagonists global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Peptides segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Gonadotropin-releasing Hormone Antagonists include AbbVie, Takeda, Astellas, Kissei, and Veru Inc, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Gonadotropin-releasing Hormone Antagonists market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Peptides
Small Molecules
Market segment by Application can be divided into
Prostate Cancer
Endometriosis
Uterine Fibroids
Female Infertility
Others
The key market players for global Gonadotropin-releasing Hormone Antagonists market are listed below:
AbbVie
Takeda
Astellas
Kissei
Veru Inc
Myovant Sciences
AstraZeneca
Ferring Pharmaceuticals
Jiangsu Hengrui Medicine Co
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Gonadotropin-releasing Hormone Antagonists product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Gonadotropin-releasing Hormone Antagonists, with price, sales, revenue and global market share of Gonadotropin-releasing Hormone Antagonists from 2019 to 2022.
Chapter 3, the Gonadotropin-releasing Hormone Antagonists competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Gonadotropin-releasing Hormone Antagonists breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Gonadotropin-releasing Hormone Antagonists market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Gonadotropin-releasing Hormone Antagonists.
Chapter 13, 14, and 15, to describe Gonadotropin-releasing Hormone Antagonists sales channel, distributors, customers, research findings and conclusion, appendix and data source.

❖ レポートの目次 ❖

1 Market Overview
1.1 Gonadotropin-releasing Hormone Antagonists Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Gonadotropin-releasing Hormone Antagonists Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Peptides
1.2.3 Small Molecules
1.3 Market Analysis by Application
1.3.1 Overview: Global Gonadotropin-releasing Hormone Antagonists Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Prostate Cancer
1.3.3 Endometriosis
1.3.4 Uterine Fibroids
1.3.5 Female Infertility
1.3.6 Others
1.4 Global Gonadotropin-releasing Hormone Antagonists Market Size & Forecast
1.4.1 Global Gonadotropin-releasing Hormone Antagonists Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Gonadotropin-releasing Hormone Antagonists Sales in Volume (2017-2028)
1.4.3 Global Gonadotropin-releasing Hormone Antagonists Price (2017-2028)
1.5 Global Gonadotropin-releasing Hormone Antagonists Production Capacity Analysis
1.5.1 Global Gonadotropin-releasing Hormone Antagonists Total Production Capacity (2017-2028)
1.5.2 Global Gonadotropin-releasing Hormone Antagonists Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Gonadotropin-releasing Hormone Antagonists Market Drivers
1.6.2 Gonadotropin-releasing Hormone Antagonists Market Restraints
1.6.3 Gonadotropin-releasing Hormone Antagonists Trends Analysis
2 Manufacturers Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Gonadotropin-releasing Hormone Antagonists Product and Services
2.1.4 AbbVie Gonadotropin-releasing Hormone Antagonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Takeda
2.2.1 Takeda Details
2.2.2 Takeda Major Business
2.2.3 Takeda Gonadotropin-releasing Hormone Antagonists Product and Services
2.2.4 Takeda Gonadotropin-releasing Hormone Antagonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Astellas
2.3.1 Astellas Details
2.3.2 Astellas Major Business
2.3.3 Astellas Gonadotropin-releasing Hormone Antagonists Product and Services
2.3.4 Astellas Gonadotropin-releasing Hormone Antagonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Kissei
2.4.1 Kissei Details
2.4.2 Kissei Major Business
2.4.3 Kissei Gonadotropin-releasing Hormone Antagonists Product and Services
2.4.4 Kissei Gonadotropin-releasing Hormone Antagonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Veru Inc
2.5.1 Veru Inc Details
2.5.2 Veru Inc Major Business
2.5.3 Veru Inc Gonadotropin-releasing Hormone Antagonists Product and Services
2.5.4 Veru Inc Gonadotropin-releasing Hormone Antagonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Myovant Sciences
2.6.1 Myovant Sciences Details
2.6.2 Myovant Sciences Major Business
2.6.3 Myovant Sciences Gonadotropin-releasing Hormone Antagonists Product and Services
2.6.4 Myovant Sciences Gonadotropin-releasing Hormone Antagonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 AstraZeneca
2.7.1 AstraZeneca Details
2.7.2 AstraZeneca Major Business
2.7.3 AstraZeneca Gonadotropin-releasing Hormone Antagonists Product and Services
2.7.4 AstraZeneca Gonadotropin-releasing Hormone Antagonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Ferring Pharmaceuticals
2.8.1 Ferring Pharmaceuticals Details
2.8.2 Ferring Pharmaceuticals Major Business
2.8.3 Ferring Pharmaceuticals Gonadotropin-releasing Hormone Antagonists Product and Services
2.8.4 Ferring Pharmaceuticals Gonadotropin-releasing Hormone Antagonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Jiangsu Hengrui Medicine Co
2.9.1 Jiangsu Hengrui Medicine Co Details
2.9.2 Jiangsu Hengrui Medicine Co Major Business
2.9.3 Jiangsu Hengrui Medicine Co Gonadotropin-releasing Hormone Antagonists Product and Services
2.9.4 Jiangsu Hengrui Medicine Co Gonadotropin-releasing Hormone Antagonists Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Gonadotropin-releasing Hormone Antagonists Breakdown Data by Manufacturer
3.1 Global Gonadotropin-releasing Hormone Antagonists Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Gonadotropin-releasing Hormone Antagonists Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Gonadotropin-releasing Hormone Antagonists
3.4 Market Concentration Rate
3.4.1 Top 3 Gonadotropin-releasing Hormone Antagonists Manufacturer Market Share in 2021
3.4.2 Top 6 Gonadotropin-releasing Hormone Antagonists Manufacturer Market Share in 2021
3.5 Global Gonadotropin-releasing Hormone Antagonists Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Gonadotropin-releasing Hormone Antagonists Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Gonadotropin-releasing Hormone Antagonists Market Size by Region
4.1.1 Global Gonadotropin-releasing Hormone Antagonists Sales in Volume by Region (2017-2028)
4.1.2 Global Gonadotropin-releasing Hormone Antagonists Revenue by Region (2017-2028)
4.2 North America Gonadotropin-releasing Hormone Antagonists Revenue (2017-2028)
4.3 Europe Gonadotropin-releasing Hormone Antagonists Revenue (2017-2028)
4.4 Asia-Pacific Gonadotropin-releasing Hormone Antagonists Revenue (2017-2028)
4.5 South America Gonadotropin-releasing Hormone Antagonists Revenue (2017-2028)
4.6 Middle East and Africa Gonadotropin-releasing Hormone Antagonists Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Gonadotropin-releasing Hormone Antagonists Sales in Volume by Type (2017-2028)
5.2 Global Gonadotropin-releasing Hormone Antagonists Revenue by Type (2017-2028)
5.3 Global Gonadotropin-releasing Hormone Antagonists Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Gonadotropin-releasing Hormone Antagonists Sales in Volume by Application (2017-2028)
6.2 Global Gonadotropin-releasing Hormone Antagonists Revenue by Application (2017-2028)
6.3 Global Gonadotropin-releasing Hormone Antagonists Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Gonadotropin-releasing Hormone Antagonists Sales by Type (2017-2028)
7.2 North America Gonadotropin-releasing Hormone Antagonists Sales by Application (2017-2028)
7.3 North America Gonadotropin-releasing Hormone Antagonists Market Size by Country
7.3.1 North America Gonadotropin-releasing Hormone Antagonists Sales in Volume by Country (2017-2028)
7.3.2 North America Gonadotropin-releasing Hormone Antagonists Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Gonadotropin-releasing Hormone Antagonists Sales by Type (2017-2028)
8.2 Europe Gonadotropin-releasing Hormone Antagonists Sales by Application (2017-2028)
8.3 Europe Gonadotropin-releasing Hormone Antagonists Market Size by Country
8.3.1 Europe Gonadotropin-releasing Hormone Antagonists Sales in Volume by Country (2017-2028)
8.3.2 Europe Gonadotropin-releasing Hormone Antagonists Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Gonadotropin-releasing Hormone Antagonists Sales by Type (2017-2028)
9.2 Asia-Pacific Gonadotropin-releasing Hormone Antagonists Sales by Application (2017-2028)
9.3 Asia-Pacific Gonadotropin-releasing Hormone Antagonists Market Size by Region
9.3.1 Asia-Pacific Gonadotropin-releasing Hormone Antagonists Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Gonadotropin-releasing Hormone Antagonists Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Gonadotropin-releasing Hormone Antagonists Sales by Type (2017-2028)
10.2 South America Gonadotropin-releasing Hormone Antagonists Sales by Application (2017-2028)
10.3 South America Gonadotropin-releasing Hormone Antagonists Market Size by Country
10.3.1 South America Gonadotropin-releasing Hormone Antagonists Sales in Volume by Country (2017-2028)
10.3.2 South America Gonadotropin-releasing Hormone Antagonists Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Gonadotropin-releasing Hormone Antagonists Sales by Type (2017-2028)
11.2 Middle East & Africa Gonadotropin-releasing Hormone Antagonists Sales by Application (2017-2028)
11.3 Middle East & Africa Gonadotropin-releasing Hormone Antagonists Market Size by Country
11.3.1 Middle East & Africa Gonadotropin-releasing Hormone Antagonists Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Gonadotropin-releasing Hormone Antagonists Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Gonadotropin-releasing Hormone Antagonists and Key Manufacturers
12.2 Manufacturing Costs Percentage of Gonadotropin-releasing Hormone Antagonists
12.3 Gonadotropin-releasing Hormone Antagonists Production Process
12.4 Gonadotropin-releasing Hormone Antagonists Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Gonadotropin-releasing Hormone Antagonists Typical Distributors
13.3 Gonadotropin-releasing Hormone Antagonists Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ゴナドトロピン放出ホルモン拮抗薬の世界市場2022：ペプチド、低分子(Global Gonadotropin-releasing Hormone Antagonists Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

ゴナドトロピン放出ホルモン拮抗薬の世界市場2022：ペプチド、低分子

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp